" Kazia CEO, Dr James Garner, commented, “China is one of the...

" Kazia CEO, Dr James Garner, commented, “China is one of the world’s largest
pharmaceutical markets, with specific requirements and opportunities for innovative
oncology products. We are delighted to partner with Simcere to secure the commercial
success of paxalisib in this critical territory. Simcere’s track record of success is unrivalled,
and they bring to paxalisib first-class capabilities in clinical development, regulatory affairs,
and commercialisation. We look forward to working closely with our new partners to make
paxalisib available for Chinese patients as swiftly as possible.”

Dr Renhong Tang, Senior Vice President at Simcere, added, “we are tremendously excited by
the potential for paxalisib to make a difference in this very challenging disease. The need for
new therapies in brain cancer is significant in China, and we share Kazia’s commitment to
bringing forward new treatment options for patients.” "


"Kazia is pleased to invite investors to attend a conference call to further discuss the
partnership with Simcere.

The call will be held on Tuesday 30 March 2021 at 8:00am, Sydney time (AEDT), which is
5:00pm on 29 March in New York (ET) and 2:00pm on 29 March in San Francisco (PT).
Participants will need to pre-register for the call via the following link:"